Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis

Kevin R. Flaherty, Martin Kolb, Carlo Vancheri, Wenbo Tang, Craig S. Conoscenti, Luca Richeldi

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS® trials and FVC changes in the open-label extension trial INPULSIS®-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS®. Analyses were descriptive. Based on the annual rate of change in FVC, 158 of 638 patients (24.8%) treated with nintedanib and 38 of 423 patients (9.0%) treated with placebo had an improvement/no decline in FVC in the INPULSIS® trials. In patients whose FVC improved/did not decline, median (interquartile range) improvements in FVC at week 52 were 76.5 (31-152) mL and 57.5 (31-103) mL in the nintedanib and placebo groups, respectively. Changes in FVC from baseline to week 48 of INPULSIS®-ON were similar in patients whose FVC improved or declined in the preceding INPULSIS® trial. In the INPULSIS® trials, treatment with nintedanib resulted in a greater proportion of patients with IPF showing an improvement/no decline in FVC compared to taking placebo. Mechanisms underlying improvement in FVC in patients with IPF are unknown.

Original languageEnglish
Article number1702593
JournalEuropean Respiratory Journal
Volume52
Issue number2
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Idiopathic Pulmonary Fibrosis
Vital Capacity
Placebos
nintedanib

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. / Flaherty, Kevin R.; Kolb, Martin; Vancheri, Carlo; Tang, Wenbo; Conoscenti, Craig S.; Richeldi, Luca.

In: European Respiratory Journal, Vol. 52, No. 2, 1702593, 01.08.2018.

Research output: Contribution to journalArticle

Flaherty, Kevin R. ; Kolb, Martin ; Vancheri, Carlo ; Tang, Wenbo ; Conoscenti, Craig S. ; Richeldi, Luca. / Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis. In: European Respiratory Journal. 2018 ; Vol. 52, No. 2.
@article{6f1e8fd5cd9b4e909dbbadb57cd9966e,
title = "Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis",
abstract = "In the Phase III INPULSIS{\circledR} trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS{\circledR} trials and FVC changes in the open-label extension trial INPULSIS{\circledR}-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS{\circledR}. Analyses were descriptive. Based on the annual rate of change in FVC, 158 of 638 patients (24.8{\%}) treated with nintedanib and 38 of 423 patients (9.0{\%}) treated with placebo had an improvement/no decline in FVC in the INPULSIS{\circledR} trials. In patients whose FVC improved/did not decline, median (interquartile range) improvements in FVC at week 52 were 76.5 (31-152) mL and 57.5 (31-103) mL in the nintedanib and placebo groups, respectively. Changes in FVC from baseline to week 48 of INPULSIS{\circledR}-ON were similar in patients whose FVC improved or declined in the preceding INPULSIS{\circledR} trial. In the INPULSIS{\circledR} trials, treatment with nintedanib resulted in a greater proportion of patients with IPF showing an improvement/no decline in FVC compared to taking placebo. Mechanisms underlying improvement in FVC in patients with IPF are unknown.",
author = "Flaherty, {Kevin R.} and Martin Kolb and Carlo Vancheri and Wenbo Tang and Conoscenti, {Craig S.} and Luca Richeldi",
year = "2018",
month = "8",
day = "1",
doi = "10.1183/13993003.02593-2017",
language = "English",
volume = "52",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - Stability or improvement in forced vital capacity with nintedanib in patients with idiopathic pulmonary fibrosis

AU - Flaherty, Kevin R.

AU - Kolb, Martin

AU - Vancheri, Carlo

AU - Tang, Wenbo

AU - Conoscenti, Craig S.

AU - Richeldi, Luca

PY - 2018/8/1

Y1 - 2018/8/1

N2 - In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS® trials and FVC changes in the open-label extension trial INPULSIS®-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS®. Analyses were descriptive. Based on the annual rate of change in FVC, 158 of 638 patients (24.8%) treated with nintedanib and 38 of 423 patients (9.0%) treated with placebo had an improvement/no decline in FVC in the INPULSIS® trials. In patients whose FVC improved/did not decline, median (interquartile range) improvements in FVC at week 52 were 76.5 (31-152) mL and 57.5 (31-103) mL in the nintedanib and placebo groups, respectively. Changes in FVC from baseline to week 48 of INPULSIS®-ON were similar in patients whose FVC improved or declined in the preceding INPULSIS® trial. In the INPULSIS® trials, treatment with nintedanib resulted in a greater proportion of patients with IPF showing an improvement/no decline in FVC compared to taking placebo. Mechanisms underlying improvement in FVC in patients with IPF are unknown.

AB - In the Phase III INPULSIS® trials, nintedanib reduced the annual rate of decline in forced vital capacity (FVC) versus placebo in patients with idiopathic pulmonary fibrosis (IPF). We conducted post hoc analyses of the distribution of changes in FVC in the INPULSIS® trials and FVC changes in the open-label extension trial INPULSIS®-ON in subgroups of patients based on whether patients had shown an improvement or no decline in FVC in INPULSIS®. Analyses were descriptive. Based on the annual rate of change in FVC, 158 of 638 patients (24.8%) treated with nintedanib and 38 of 423 patients (9.0%) treated with placebo had an improvement/no decline in FVC in the INPULSIS® trials. In patients whose FVC improved/did not decline, median (interquartile range) improvements in FVC at week 52 were 76.5 (31-152) mL and 57.5 (31-103) mL in the nintedanib and placebo groups, respectively. Changes in FVC from baseline to week 48 of INPULSIS®-ON were similar in patients whose FVC improved or declined in the preceding INPULSIS® trial. In the INPULSIS® trials, treatment with nintedanib resulted in a greater proportion of patients with IPF showing an improvement/no decline in FVC compared to taking placebo. Mechanisms underlying improvement in FVC in patients with IPF are unknown.

UR - http://www.scopus.com/inward/record.url?scp=85051559865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051559865&partnerID=8YFLogxK

U2 - 10.1183/13993003.02593-2017

DO - 10.1183/13993003.02593-2017

M3 - Article

AN - SCOPUS:85051559865

VL - 52

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 2

M1 - 1702593

ER -